PRPO Precipio

Precipio Terminates its Equity Line

Precipio Terminates its Equity Line

NEW HAVEN, Conn., June 15, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics Company , announces that as part of management’s review of its current financing arrangements, it has terminated the equity line financing structure it had in place with .

The equity line was used by Precipio to fund day-to-day operations and cover its operational cash burn that was required for the Company’s continued growth. With the Company’s current situation - growing revenues, improved gross margins, improving cash from gross profits - combined with our current cash position, management currently does not anticipate the need for additional capital raises of the type that Lincoln Park has provided us.

“I’d like to thank our friends at Lincoln Park Capital for their help and support of the Company, particularly during the periods where this arrangement was critical to the Company’s cash needs,” said Ilan Danieli, Precipio’s CEO. “We are now in a position where we have significantly extended our runway, and we anticipate that we will have the ability and the resources to rapidly grow the Company without further capital raises to fund ongoing operations in the next 24 months.”

About Precipio

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard’s Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit .

Please follow us on Twitter and on . 

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the Company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the Company’s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the Company’s business, operations and employees and the other factors that are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as updated from time to time in the Company’s Securities and Exchange Commission filings.

The Company’s forward-looking statements in this press release are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.



Inquiries:

 

  Ext. 523
EN
15/06/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Precipio

 PRESS RELEASE

Precipio Announces Q4 and year-end 2025 Shareholder Update Call

Precipio Announces Q4 and year-end 2025 Shareholder Update Call Conference Call to be held on April 2nd, 2026 at 5:00 PM EST NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  , will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Listeners interested in submitting questions in advance should email their...

 PRESS RELEASE

Precipio Announces Publication of a Joint Study with Memorial Sloan-Ke...

Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company   has announced the 1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Cancer Center, demonstrating Precipio’s new Bloodhound assay for Chronic Myeloid Leukemia (CML). According to the...

 PRESS RELEASE

Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year...

Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M NEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  , announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics for the Company. Revenue Growth – Precipio’s revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an ...

 PRESS RELEASE

Precipio Takes Major Steps Toward a Clean Balance Sheet

Precipio Takes Major Steps Toward a Clean Balance Sheet Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstanding NEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company   has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major obligation repaid A $1.1 million advance from Change Healthcare (“CHC”), the Company’s clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collection...

 PRESS RELEASE

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society...

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient care NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company   will be presenting at ASH the findings of a joint study conducted with scientific collaborators from in New York, evaluating Precipio’s BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing con...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch